Class-action securities suit goes forward against Amgen

A U.S. appeals court will let Amgen ($AMGN) investors keep their class-action status in a complaint accusing the company of failing to fully disclose potential safety problems with its anemia drugs Epogen and Aranesp. The shareholder that originally filed the suit also alleges Amgen promoted significant off-label use of the drugs. Report

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”